Main Objectives

• To evaluate the effect of AD treatments on the PharmaCog biomarker battery in both healthy volunteers and AD patients to determine sensitive markers of clinical pharmacology and support dose selection studies.
• To establish mathematical models that describe the relationship between drug exposure and pharmacodynamic marker response and between responses in HVT and patients in order to support future clinical study design
• Back-translate data generated to parallel pre-clinical studies (WP4) to identify those biomarkers with translational capacity to improve the predictive capacity of pre-clinical models

WP Leads

Academic Lead: Pr Régis Bordet (University of Lille, France) and Dr Pierre Payoux (INSERM, Toulouse)

WP Partners

• UnivMed, France
• University of Lille, France
• INSERM, France
• University of Foggia, Italy
• Qualissima
• Eisai Ltd